2020
Smoking and HIV associated with subclinical tuberculosis: analysis of a population-based prevalence survey
Gunasekera K, Cohen T, Gao W, Ayles H, Godfrey-Faussett P, Claassens M. Smoking and HIV associated with subclinical tuberculosis: analysis of a population-based prevalence survey. The International Journal Of Tuberculosis And Lung Disease 2020, 24: 340-346. PMID: 32228765, DOI: 10.5588/ijtld.19.0387.Peer-Reviewed Original ResearchConceptsActive TBPrevalence surveyPopulation-based prevalence surveyCurrent tobacco smokingTypical symptomsHIV-positive statusTuberculosis prevalence surveyPrevalence survey dataSubclinical tuberculosisPositive TBCrude prevalenceTobacco smokingEpidemiological burdenPrevalent casesReduction TrialSubclinical TBMedical variablesSecondary analysisEstimate associationsSouth African communitySymptomsHIVSmokingTuberculosisDisease
2016
High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions
Marx FM, Floyd S, Ayles H, Godfrey-Faussett P, Beyers N, Cohen T. High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions. European Respiratory Journal 2016, 48: 1227-1230. PMID: 27390274, PMCID: PMC5512114, DOI: 10.1183/13993003.00716-2016.Peer-Reviewed Original ResearchConceptsHigh-burden settingsHigh TB prevalenceRecurrent tuberculosisExogenous reinfectionPrevalent tuberculosisTB prevalenceSuccessful treatmentHigh burdenImportant underlying mechanismHigh riskHigh incidenceControl interventionsTargeted interventionsTuberculosisUnderlying mechanismOne-thirdInterventionBurdenCape TownIndividualsReinfectionPrevalenceIncidenceDiseaseSetting
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility